2199 related articles for article (PubMed ID: 34550000)
1. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
3. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.
Liu C; Yu X; Gao C; Zhang L; Zhai H; Hu Y; Liu E; Wang Q; Gao Y; Wei D; Zhang D; Han Y; Zhang X
J Med Virol; 2021 Apr; 93(4):2227-2233. PubMed ID: 33135795
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
[TBL] [Abstract][Full Text] [Related]
5. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
6. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V
Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795
[TBL] [Abstract][Full Text] [Related]
7. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.
Zhang X; Lu S; Li H; Wang Y; Lu Z; Liu Z; Lai Q; Ji Y; Huang X; Li Y; Sun J; Wu Y; Xu X; Hou J
Virol Sin; 2020 Dec; 35(6):820-829. PubMed ID: 33351168
[TBL] [Abstract][Full Text] [Related]
8. Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.
Xiang T; Liang B; Fang Y; Lu S; Li S; Wang H; Li H; Yang X; Shen S; Zhu B; Wang B; Wu J; Liu J; Lu M; Yang D; Dittmer U; Trilling M; Deng F; Zheng X
Front Immunol; 2021; 12():708523. PubMed ID: 34220870
[TBL] [Abstract][Full Text] [Related]
9. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
10. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
12. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
13. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies.
Bubonja-Šonje M; Batičić L; Abram M; Cekinović Grbeša Đ
J Virol Methods; 2021 Jul; 293():114173. PubMed ID: 33930473
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
16. Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.
De Giorgi V; West KA; Henning AN; Chen LN; Holbrook MR; Gross R; Liang J; Postnikova E; Trenbeath J; Pogue S; Scinto T; Alter HJ; Cantilena CC
J Infect Dis; 2021 Oct; 224(8):1294-1304. PubMed ID: 34089610
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
18. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC
Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172
[TBL] [Abstract][Full Text] [Related]
19. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.
Harrington WE; Trakhimets O; Andrade DV; Dambrauskas N; Raappana A; Jiang Y; Houck J; Selman W; Yang A; Vigdorovich V; Yeung W; Haglund M; Wallner J; Oldroyd A; Hardy S; Stewart SWA; Gervassi A; Van Voorhis W; Frenkel L; Sather DN
Cell Rep Med; 2021 Apr; 2(4):100253. PubMed ID: 33842901
[TBL] [Abstract][Full Text] [Related]
20. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections.
Lei Q; Li Y; Hou HY; Wang F; Ouyang ZQ; Zhang Y; Lai DY; Banga Ndzouboukou JL; Xu ZW; Zhang B; Chen H; Xue JB; Lin XS; Zheng YX; Yao ZJ; Wang XN; Yu CZ; Jiang HW; Zhang HN; Qi H; Guo SJ; Huang SH; Sun ZY; Tao SC; Fan XL
Allergy; 2021 Feb; 76(2):551-561. PubMed ID: 33040337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
